Poly-S-nitrosated albumin as a safe and effective multifunctional antitumor agent: Characterization, biochemistry and possible future therapeutic applications

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Ishima, Yu ^a   Kragh Hansen, Ulrich ^b   Maruyama, Toru ^a   Otagiri, Masaki ^a,c  

^a KUMAMOTO UNIVERSITY   (Japan)

^b AARHUS UNIVERSITY   (Denmark)

^c SOJO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; CASPASE 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NITRIC OXIDE; NITRIC OXIDE DONOR; POLY S NITROSATED ALBUMIN; S NITROSOTHIOL; UNCLASSIFIED DRUG; NITROSO DERIVATIVE; S NITROSOALBUMIN, HUMAN; S-NITROSOALBUMIN, HUMAN; SERUM ALBUMIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CELL PROLIFERATION; CYTOTOXICITY; DNA FRAGMENTATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; ENZYME ACTIVATION; HEMODYNAMICS; HUMAN; METASTASIS; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NONHUMAN; REVIEW; BLOOD; CHEMISTRY; DRUG EFFECT; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; S-NITROSOTHIOLS; SERUM ALBUMIN;

EID: 84896099330     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/353892     Document Type: Review

References (57)

1. Moncada S., Palmer R. M. J., Higgs E. A., Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacological Reviews 1991 43 2 109 142 2-s2.0-0025883342
2. Mizutani T., Layon A. J., Clinical applications of nitric oxide. Chest 1996 110 2 506 524 2-s2.0-0029757425 (Pubitemid 26269285)
3. Stamler J. S., Singel D. J., Loscalzo J., Biochemistry of nitric oxide and its redox-activated forms. Science 1992 258 5090 1898 1902 2-s2.0-0027104253 (Pubitemid 23026727)
4. Nathan C., Nitric oxide as a secretory product of mammalian cells. FASEB Journal 1992 6 12 3051 3064 2-s2.0-0026629902
5. Lancaster J. R. Jr., Simulation of the diffusion and reaction of endogenously produced nitric oxide. Proceedings of the National Academy of Sciences of the United States of America 1994 91 17 8137 8141 2-s2.0-0027992219 10.1073/pnas.91.17.8137 (Pubitemid 24253901)
6. Gaston B., Reilly J., Drazen J. M., Fackler J., Ramdev P., Arnelle D., Mullins M. E., Sugarbaker D. J., Chee C., Singel D. J., Loscalzo J., Stamler J. S., Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proceedings of the National Academy of Sciences of the United States of America 1993 90 23 10957 10961 2-s2.0-0027515050 10.1073/pnas.90.23.10957 (Pubitemid 23354347)
7. Clancy R. M., Levartovsky D., Leszczynska-Piziak J., Yegudin J., Abramson S. B., Nitric oxide reacts with intracellular glutathione and activates the hexose monophosphate shunt in human neutrophils: evidence for S- nitrosoglutathione as a bioactive intermediary. Proceedings of the National Academy of Sciences of the United States of America 1994 91 9 3680 3684 2-s2.0-0028287096
8. Furchgott R. F., Zawadzki J. V., The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980 288 5789 373 376 2-s2.0-0019195506 (Pubitemid 11169009)
9. Palmer R. M. J., Ferrige A. G., Moncada S., Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987 327 6122 524 526 2-s2.0-0023198721 (Pubitemid 17085822)
10. Radomski M. W., Palmer R. M., Moncada S., The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. British Journal of Pharmacology 1987 92 3 639 646 2-s2.0-0023446425
11. Dawson T. M., Snyder S. H., Gases as biological messengers: nitric oxide and carbon monoxide in the brain. Journal of Neuroscience 1994 14 9 5147 5159 2-s2.0-0027939807 (Pubitemid 24279040)
12. Ignarro L. J., Napoli C., Loscalzo J., Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circulation Research 2002 90 1 21 28 2-s2.0-0037059510 10.1161/hh0102.102330 (Pubitemid 34074604)
13. Fung H.-L., Biochemical mechanism of nitroglycerin action and tolerance: is this old mystery solved? Annual Review of Pharmacology and Toxicology 2004 44 67 85 2-s2.0-1342281276 10.1146/annurev.pharmtox.44.101802.121646 (Pubitemid 38263834)
14. Ishima Y., Yoshida F., Kragh-Hansen U., Watanabe K., Katayama N., Nakajou K., Akaike T., Kai T., Maruyama T., Otagiri M., Cellular uptake mechanisms and responses to NO transferred from mono-and poly-S-nitrosated human serum albumin. Free Radical Research 2011 45 10 1196 1206 2-s2.0-80052706434 10.3109/10715762.2011.606814
15. Hibbs J. B. Jr., Taintor R. R., Vavrin Z., Rachlin E. M., Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochemical and Biophysical Research Communications 1988 157 1 87 94 2-s2.0-0024244657 (Pubitemid 19004828)
16. Beckman J. S., Crow J. P., Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochemical Society Transactions 1993 21 2 330 334 2-s2.0-0027280338 (Pubitemid 23167917)
17. Isobe M., Katsuramaki T., Hirata K., Kimura H., Nagayama M., Matsuno T., Beneficial effects of inducible nitric oxide synthase inhibitor on reperfusion injury in the pig liver. Transplantation 1999 68 6 803 813 2-s2.0-0033610282 10.1097/00007890-199909270-00013 (Pubitemid 29468199)
18. Beckman J. S., Beckman T. W., Chen J., Marshall P. A., Freeman B. A., Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proceedings of the National Academy of Sciences of the United States of America 1990 87 4 1620 1624 2-s2.0-0025189864
19. Virág L., Szabó E., Gergely P., Szabó C., Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicology Letters 2003 140-141 113 124 10.1016/S0378-4274(02) 00508-8 (Pubitemid 36378929)
20. Szabó C., Hydrogen sulphide and its therapeutic potential. Nature Reviews Drug Discovery 2007 6 917 935 10.1038/nrd2425 (Pubitemid 350042399)
21. Salvemini D., Jensen M. P., Riley D. P., Misko T. P., Therapeutic manipulations of peroxynitrite. Drug News and Perspectives 1998 11 4 204 214 2-s2.0-0031826004
22. Friederich J. A., Butterworth J. F. IV, Sodium nitroprusside: twenty years and counting. Anesthesia and Analgesia 1995 81 1 152 162 2-s2.0-0029070270 10.1097/00000539-199507000-00031
23. Robin E. D., McCauley R., Nitroprusside-related cyanide poisoning; time (long past due) for urgent, effective interventions. Chest 1992 102 6 1842 1845 2-s2.0-0026685875 (Pubitemid 23001239)
24. Saavedra J. E., Billiar T. R., Williams D. L., Kim Y.-M., Watkins S. C., Keefer L. K., Targeting nitric oxide (NO) delivery in vivo. Design of a liver- selective NO donor prodrug that blocks tumor necrosis factor- α-induced apoptosis and toxicity in the liver. Journal of Medicinal Chemistry 1997 40 13 1947 1954 2-s2.0-0030918451 10.1021/jm9701031 (Pubitemid 27265970)
25. Ricciardi R., Schaffer B. K., Kim R. D., Shah S. A., Donohue S. E., Wheeler S. M., Quarfordt S. H., Callery M. P., Meyers W. C., Chari R. S., Protective effects of ischemic preconditioning on the cold-preserved liver are tyrosine kinase dependent. Transplantation 2001 72 3 406 412 2-s2.0-0035882134 (Pubitemid 32769623)
26. Liu J., Li C., Waalkes M. P., Clark J., Myers P., Saavedra J. E., Keefer L. K., The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen- induced hepatotoxicity in mice. Hepatology 2003 37 2 324 333 2-s2.0-0037308128 10.1053/jhep.2003.50063 (Pubitemid 36152531)
27. Fiorucci S., Antonelli E., Tocchetti P., Morelli A., Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status. Cardiovascular Drug Reviews 2004 22 2 135 146 2-s2.0-3042789989 (Pubitemid 38879877)
28. Katsumi H., Nishikawa M., Hashida M., Development of nitric oxide donors for the treatment of cardiovascular diseases. Cardiovascular and Hematological Agents in Medicinal Chemistry 2007 5 3 204 208 2-s2.0-34547521265 10.2174/187152507781058735
29. Katayama N., Nakajou K., Komori H., Uchida K., Yokoe J.-I., Yasui N., Yamamoto H., Kai T., Sato M., Nakagawa T., Takeya M., Maruyama T., Otagiri M., Design and evaluation of S-nitrosylated human serum albumin as a novel anticancer drug. Journal of Pharmacology and Experimental Therapeutics 2008 325 1 69 76 2-s2.0-41149092508 10.1124/jpet.107.132100 (Pubitemid 351439161)
30. Katayama N., Nakajou K., Ishima Y., Ikuta S., Yokoe J.-I., Yoshida F., Suenaga A., Maruyama T., Kai T., Otagiri M., Nitrosylated human serum albumin (SNO-HSA) induces apoptosis in tumor cells. Nitric Oxide 2010 22 4 259 265 2-s2.0-77949884806 10.1016/j.niox.2009.09.003
31. Stamler J. S., Jaraki O., Osborne J., Simon D. I., Keaney J., Vita J., Singel D., Valeri C. R., Loscalzo J., Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proceedings of the National Academy of Sciences of the United States of America 1992 89 16 7674 7677 2-s2.0-0026693724
32. Marley R., Feelisch M., Holt S., Moore K., A chemiluminescense-based assay for S-nitrosoalbumin and other plasma S-nitrosothiols. Free Radical Research 2000 32 1 1 9 2-s2.0-0033988226 (Pubitemid 30010603)
33. Ishima Y., Hara M., Kragh-Hansen U., Inoue A., Suenaga A., Kai T., Watanabe H., Otagiri M., Maruyama T., Elucidation of the therapeutic enhancer mechanism of poly-S-nitrosated human serum albumin against multidrug-resistant tumor in animal models. Journal of Controlled Release 2012 164 1 7 10.1016/j.jconrel.2012.10.003
34. Marks D. S., Vita J. A., Folts J. D., Keaney J. F. Jr., Welch G. N., Loscalzo J., Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. Journal of Clinical Investigation 1995 96 6 2630 2638 2-s2.0-0028787682
35. Ewing J. F., Young D. V., Janero D. R., Garvey D. S., Grinnell T. A., Nitrosylated bovine serum albumin derivatives as pharmacologically active nitric oxide congeners. Journal of Pharmacology and Experimental Therapeutics 1997 283 2 947 954 2-s2.0-0030732453 (Pubitemid 27514659)
36. Baek S. H., Hrabie J. A., Keefer L. K., Hou D., Fineberg N., Rhoades R., March K. L., Augmentation of intrapericardial nitric oxide level by a prolonged-release nitric oxide donor reduces luminal narrowing after porcine coronary angioplasty. Circulation 2002 105 23 2779 2784 2-s2.0-0037062640 10.1161/01.CIR.0000017432.19415.3E (Pubitemid 34615151)
37. Katsumi H., Nishikawa M., Yamashita F., Hashida M., Development of polyethylene glycol-conjugated poly-S-nitrosated serum albumin, a novel S-nitrosothiol for prolonged delivery of nitric oxide in the blood circulation in vivo. Journal of Pharmacology and Experimental Therapeutics 2005 314 3 1117 1124 2-s2.0-23944449393 10.1124/jpet.105.087429 (Pubitemid 41205976)
38. Hirst D., Robson T., Nitric oxide in cancer therapeutics: interaction with cytotoxic chemotherapy. Current Pharmaceutical Design 2010 16 4 411 420 2-s2.0-77949463994 10.2174/138161210790232185
39. Qin Y., Dey A., Purayil H. T., Daaka Y., Maintenance of androgen receptor inactivation by S-nitrosylation. Cancer Research 2013 73 22 6690 6699 10.1158/0008-5472.CAN-13-1042
40. Kielbik M., Klink M., Brzezinska M., Szulc I., Sulowska Z., Nitric oxide donors: spermine/NO and diethylenetriamine/NO induce ovarian cancer cell death and affect STAT3 and AKT signaling proteins. Nitric Oxide 2013 35 93 109 10.1016/j.niox.2013.09.001
41. Williams J. L., Borgo S., Hasan I., Castillo E., Traganos F., Rigas B., Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Research 2001 61 8 3285 3289 2-s2.0-0035870291 (Pubitemid 32695014)
42. Gao J., Liu X., Rigas B., Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proceedings of the National Academy of Sciences of the United States of America 2005 102 47 17207 17212 2-s2.0-28044436484 10.1073/pnas.0506893102 (Pubitemid 41692708)
43. Kogias E., Osterberg N., Baumer B., Psarras N., Koentges C., Papazoglou A., Saavedra J. E., Keefer L. K., Weyerbrock A., Growth-inhibitory and chemosensitizing effects of the glutathione-S- transferase- π -activated nitric oxide donor PABA/NO in malignant gliomas. International Journal of Cancer 2012 130 5 1184 1194 2-s2.0-84155164796 10.1002/ijc.26106
44. Duan S., Cai S., Yang Q., Forrest M. L., Multi-arm polymeric nanocarrier as a nitric oxide delivery platform for chemotherapy of head and neck squamous cell carcinoma. Biomaterials 2012 33 11 3243 3253 2-s2.0-84856562674 10.1016/j.biomaterials.2012.01.026
45. Nagai H., Yasuda H., Hatachi Y., Xue D., Sasaki T., Yamaya M., Sakamori Y., Togashi Y., Masago K., Ito I., Kim Y. H., Mio T., Mishima M., Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO-cGMP signaling in lung adenocarcinoma cells in vitro and in vivo. International Journal of Oncology 2012 41 24 30
46. Hanafy K. A., Krumenacker J. S., Murad F., NO, nitrotyrosine, and cyclic GMP in signal transduction. Medical Science Monitor 2001 7 4 801 819 2-s2.0-0034928756 (Pubitemid 32691766)
47. Quintero M., Mackenzie N., Brennan P. A., Hypoxia-inducible factor 1 (HIF-1) in cancer. European Journal of Surgical Oncology 2004 30 5 465 468 2-s2.0-2542569400 10.1016/j.ejso.2004.03.008 (Pubitemid 38701864)
48. Seeber L. M., Zweemer R. P., Verheijen R. H., van Diest P. J., Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. Obstetrics and Gynecology International 2010 2010 8 580971 10.1155/2010/580971
49. Otagiri M., Chuang V. T., Maruyama T., Kragh-Hansen U., Human serum albumin: new insights on its structural dynamics. Functional Impacts and Pharmaceutical Applications 2013 Kumamoto, Japan Sojo University Publishing Center 288 310
50. Jain R. K., Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nature Reviews Cancer 2008 8 4 309 316 2-s2.0-41149138113 10.1038/nrc2346 (Pubitemid 351430862)
51. Vredenburgh J. J., Desjardins A., Herndon J. E. II, Dowell J. M., Reardon D. A., Quinn J. A., Rich J. N., Sathornsumetee S., Gururangan S., Wagner M., Bigner D. D., Friedman A. H., Friedman H. S., Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clinical Cancer Research 2007 13 4 1253 1259 2-s2.0-33947191055 10.1158/1078-0432.CCR-06-2309 (Pubitemid 46424067)
52. Clark A. J., Lamborn K. R., Butowski N. A., Chang S. M., Prados M. D., Clarke J. L., McDermott M. W., Parsa A. T., Berger M. S., Aghi M. K., Neurosurgical management and prognosis of patients with glioblastoma that progress during bevacizumab treatment. Neurosurgery 2012 70 361 370 2-s2.0-80051541016 10.1227/NEU.0b013e3182314f9d
53. Hu Y.-L., DeLay M., Jahangiri A., Molinaro A. M., Rose S. D., Carbonell W. S., Aghi M. K., Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Research 2012 72 7 1773 1783 2-s2.0-84859385707 10.1158/0008-5472.CAN-11-3831
54. Mazure N. M., Pouysségur J., Hypoxia-induced autophagy: cell death or cell survival? Current Opinion in Cell Biology 2010 22 177 180 10.1016/j.ceb.2009.11.015
55. Leone R. D., Amaravadi R. K., Autophagy: a targetable linchpin of cancer cell metabolism. Trends in Endocrinology & Metabolism 2013 24 209 217
56. Tracy K., Dibling B. C., Spike B. T., Knabb J. R., Schumacker P., Macleod K. F., BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy. Molecular and Cellular Biology 2007 27 17 6229 6242 2-s2.0-34548235820 10.1128/MCB.02246-06 (Pubitemid 47326709)
57. Hu Y. L., Jahangiri A., Delay M., Aghi M. K., Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Research 2012 72 4294 4299 10.1158/0008-5472.CAN-12-1076